Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

AZD3293

- PMLiVE

AstraZeneca/J&J form Japanese cancer partnership

Two companies will co-promote Zytiga in prostate cancer

- PMLiVE

Lundbeck and Otsuka take Alzheimer’s drug into phase III

Lu AE58054 affects levels of serotonin in the brain

- PMLiVE

AstraZeneca advertises Crestor with ‘fun’ TV spot

TV campaign compares choice of medicine over Lipitor to sporting rivalry

- PMLiVE

AZ/Amgen report positive data with psoriasis antibody

Brodalumab shows efficacy in achieving and maintaining clear skin

- PMLiVE

New arrivals join BioHub at AZ’s Alderley Park

Six new biopharma start-ups set up at the UK biocluster

- PMLiVE

Novo backs Victoza’s prospects in Alzheimer’s

Chief science officer says phase III trial could begin in three years

- PMLiVE

AZ moves closer to EU approval for ovarian cancer drug

Olaparib on course to be first PARP inhibitor available for ovarian cancer

- PMLiVE

EMA backs drugs from Novo, Otsuka, AZ, Janssen, GSK

Nine new branded medicines recommended for use in Europe

- PMLiVE

US NIH provides $45m for Alzheimer’s research

Projects will investigate basic science of the neurological condition

- PMLiVE

FDA to review AZ’s fish oil drug Epanova

Hypertriglyceridaemia treatment acquired as part of Omthera takeover

- PMLiVE

Novo Nordisk’s Victoza shows Alzheimer’s benefits

UK scientists say the diabetes drug could reverse effects of dementia

- PMLiVE

AZ licenses Merck ovarian cancer drug

Pays $50m upfront for MK-1775

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links